Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

4-Hydroxytestosterone transdermal - Curadis

Drug Profile

4-Hydroxytestosterone transdermal - Curadis

Alternative Names: 4-hydroxy-testosterone; 4-OH-testosterone; 4-OHT - Curadis; CR 1447

Latest Information Update: 05 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Curadis
  • Developer Curadis; Swiss Group for Clinical Cancer Research
  • Class Anabolic steroids; Antineoplastics; Small molecules; Steroids; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists; Estrogen receptor alpha modulators; Estrogen receptor beta modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer

Most Recent Events

  • 27 Jun 2023 MEI Pharma terminates phase II trials in Breast cancer (Late-stage disease, Metastatic disease) in Switzerland (Transdermal) due to death of 90% of the patients (NCT02067741)
  • 25 Jun 2019 4-Hydroxytestosterone is still in phase II trials for Breast cancer (Late-stage disease) in Switzerland (Transdermal) (NCT02067741)
  • 26 Mar 2014 Curadis plans a phase II trial for Breast cancer (Late-stage disease) in Switzerland (NCT02067741)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top